New Search | Printable View
<< Previous |
Return to Search Results |
Next >>
|
Paul Timothy Fanta, M.D., M.S.
Hematology/Oncology
Cancer - Gastrointestinal
Cancer
The diagnosis and management of gastrointestinal cancers has dramatically changed in the past several years. By incorporating biotechnology, bioinformatics, molecular analyses, pharmocogenomic data, in the setting of prospective clinical trials, we may better indentify patients who will benefit from chemotherapy, avoiding toxicities from treatment, and develop a predictive therapeutic strategy unique to a patient's disease.
|
|
Board Certification:
|
Medical Oncology
Hematology
Internal Medicine
|
|
Experience:
|
August 2007-Present
Assistant Clinical Professor of Medicine, Division of Hematology-Oncology
Department of Medicine
University of California, San Diego
Clinical Oncologist in Gastrointestinal Malignancies, Clinical Trials, Collaborative Research with The Scripps Research Institute, Bayer, Pfizer.
July, 2006-June, 2007
Skaggs Research Fellow
The Scripps Research Institute, Laboratory of Dr. Paul Schimmel
Investigated endogenous anti-angiogenesis agents.
June, 1998-May1999
Medical School Research Program Fellow
Arizona Health Sciences Center, Department of Pathology,
Laboratories of Dr. Ray Nagle
Evaluated diagnosing prostate carcinoma using frozen sextant biopsies supplemented with immunohistochemistry.
July, 1996-July 1997
Laboratory Director, Arizona Cancer Center,
Tucson, Arizona
Dr. Sydney E. Salmon
Responsible for Human Tumor Clonogenic Assay and new drug screening laboratories, direct daily activities, research projects, and analyses for seven employees, responsible for all data generation, grant allocations and account requisitions, perform tissue culture, molecular analyses, fluorescence imaging, and immunohistochemistry.
July, 1990-July 1996
Senior Research Specialist, Arizona Cancer Center
Laboratory Manager for Dr. Sydney E. Salmon
Performed all human tumor clonogenic assays, gel electrophoresis, immunohistochemistry, devised new in-vitro screening techniques and assays for chemotherapeutics at the clinical level as well as phase I and II agents.
February, 1989-July 1990
-Research Assistant, Arizona Cancer Center
Responsible for all clonogenic assays on patient biopsies, helped establish tissue procurement program; aided Development Fund raising, studied chemomodulation of multi-drug resistance using Human myeloma and breast cell-lines, pilot studies using fresh human tumor biopsies.
August, 1987-February 1989
Research Assistant, Arizona Cancer Center
Evaluated all patient studies for chemosensitivity and growth, generated correspondence to physicians regarding care and handling of specimens, results of drug sensitivity assays.
,br>
July, 1986-August, 1987
Research Techician, Arizona Cancer Center
Responsible for National Cancer Institute Drug Screening; Pre-clinical evaluation of retinoic, anthracycline, and alkylating analogs, immunoconjugates and response modifiers on fresh tumors.
|
Languages other
than English:
|
None
|
|
Education:
|
Doctor of Medicine
The University of Arizona, Tucson, Arizona
Class of 2001
,br>
Master of Science, Microbiology /Immunology
The University of Arizona:
2001
Bachelor of Science. Biology, Chemistry, Math
The University of Arizona
1983
|
|
Training:
|
Fellowship: Hematology/Oncology: Scripps Clinic
La Jolla, California 2004-2007, Board-Eligible
Internal Medicine, 2004-14, NBME Certified
Internship/Residency: Internal Medicine: Scripps Clinic/Green Hospital, La Jolla, California, 2001-2004
Certificates: ACLS/CPR Certification, Health Provider, 1997-2004; Medical Student Research Program Fellow, 1998-1999; Pathogen Safety, 1994,1999; Radiation Handling Certificate, 1986
Hospital Privileges: UCSD Thorton Medical Center, UCSD Hillcrest Medical Center
Awards: Feld Award (Humanitarian Distinction), 2003; Jennifer A. Banzon Award (Intern of Year, Scripps Clinic), 2002, Norvak Pulmonary Distinction Award, 2001, Excellence in Research Award, 2001.
ABSTRACTS
Fanta, P., Pepper, I.L." Detection of Pathogenic Bacteria Using The Polymerase Chain Reaction". Presented research to Industrial Advisory Board Meeting, Center for Microcontamination and Control, National Science Foundation Industry/University Cooperative Research, Tucson, Arizona, November 18-19,1996, ACP-ASIM, October 11, 2002.
Taylor, C.W., Dorr, R.T., Fanta, P., Hersh, E., Salmon, S.E. "A Phase I and Pharmacodynamic Evaluation of PEG-L-Asparaginase in Patients with Advanced Solid Tumors" Presented at the 2001, American Society of Clinical Oncology Annual Meeting, 2001.
Fanta, P., Dalkin, B., Nagle, R. "An Evaluation of Frozen Sextant Biopsies Supplemented with Basal Cell Specific Cytokeratin Immunohistochemistry". Journal of Investigative Medicine, Vol. 47,No. 2, February, 1999, page 81A. Presented data at the Western Region Meeting of the American Federation for Medical Research, January 30, 1999.
Alberts, D.S., Emerson, J., Thompson, F., Taetle, R., Grogan, T., Yun, L., Frutiger, E., Fanta, P., Running, K., Federico, M., Salmon, S.E. "Studies of the Pathogenesis and Prognosis of Previously Untreated, Epithelial Type Ovarian Cancer". Proc. Amer. Assoc. Cancer. Res. San Francisco, CA., April 10-13, 1994.
Salmon, S.E., Fanta, P., Kottman, A. and Hersh, E. " Imexon Exhibits Selective In-Vitro Anti-tumor Activity Against Human Multiple Myeloma". Proc. Amer. Assoc. Cancer Res., May 19-21, 1993.
Alberts D.S., Garcia, D., Roe, D., Fanta, P., Liu, R., Salmon, S.E. "Comparative Cytotoxicity of Taxol and Taxotere In- Vitro Against Fresh Human Ovarian Cancers". Proc. Amer.Soc.Clin.Onc., May 17-19, San Diego, CA (Vol. 2, #719), 1992.
Alberts, D.S., Garcia, D., Roe, D., Fanta, P., Liu, R., Salmon, S.E. "Lack of Tetraplatin Cross-Resistance With Cisplatin Against Epithelial Ovarian Cancers Obtained from more than 70 Patients with Advanced Disease". Proc.Amer.Assoc.Cancer.Res., Houston, TX, May 15-18, 1992.
PUBLICATIONS
Fanta, P., Saven, A., Book Chapter “Hairy Cell Leukemia” in Rare Hematological Malignancies, Edited by Stephen M. Ansell, MD, PhD, Springer Publishing, 2007.
Bauer, J., Fanta, P., Andrey, J., "Hemoglobin Lepore: An Unusual Presentation of Microcytic Anemia", October 15, 2005, Proceedings of the American College of Physicians.
Taylor, C.W., Dorr, R.T., Fanta, P., Hersh, E., Salmon, S.E. "A Phase I and Pharmacodynamic Evaluation of PEG-L-Asparaginase in Patients with Advanced Solid Tumors" Cancer Chemotherapy and Pharmacology, Volume 47, Number 1, January, 2001, pages 83-88.
Scott, K., Fanta, P., Calaluce, R., Dalkin, B., Weinstein, R.S., Nagle, R., "Diagnostic Frozen Sextant Biopsies: An Approach for Preserving Protein and RNA for Additional Studies." The Prostate, 2000(September) 44: pages 296-302.
Monk, B.J., Alberts, D.S., Burger, R.A., Fanta, P., Hallum, A.V., Salmon, S.E. "In-vitro Phase II Comparison of the Cytotoxicity of a Novel Platinum Analog, Nedaplatin (254-S), with that of Cisplatin and Carboplatin Against Fresh Human Cervical Cancers". Gynecologic Oncology, Volume 71, pages. 308-312, 1998.
Alberts, D.S., Fanta, P., Running, K., Liu-Stevens, R., Salmon, S.E., "In-vitro Phase II Comparison of a Novel Platinum Analog, Nedaplatin (254-S), to Cisplatin and Carboplatin Against Fresh Human Ovarian Cancers". Cancer Chemotherapy and Pharmacology, 39(6): 493-497,1997.
Massimo, F., Alberts, D.S., Garcia, D., Emerson, J., Fanta, P., Liu, R., Salmon, S.E.,."In-vitro Drug Testing of Ovarian Cancer Using the Human Tumor Colony-Forming Assay: Comparison of In-vitro Response and Clinical Outcome". Gynecologic Oncology, Vol. 55, S156-S163, August, 1994.
Taylor, C.W. Liu, R., Fanta, P., Salmon, S.E., "Effects of Suramin on the in-Vitro Growth of Fresh Human Tumors". Journal of the National Cancer Institute, Volume 84. pages 489-494, 1992.
Leong, S.P.L., Xu, M.J., Alberts, D.S., Wang, T.F., Peng, Y.M., Hersh, E.M., Taylor, C.W., Fanta, P., Salmon, S.E. "Chemosensitivity of Human Melanoma to Cisplatin and Heat at Pharmacokinetic Doses Achievable by Isolated Hyperthermic Perfusion". Regional Cancer Treatment (1992) 4: pages 216-219.
Belani, R., Fanta, P., P., Schimmel, P. “Characterization of T2-TrpRS: A Potent Inhibitor of Angiogenesis”, in preparation.
|
|
Clinical Interests:
|
Cancers of the colon, rectum, anus, stomach, esophagus, GI stromal tumors, hepatocellular carcinoma, pancreas, gall- bladder, cholangiocarcinoma. Our GI cancer group is devoted to the treatment of these malignancies, and offer a multi-disciplinary approach for each patient. Clinical trial participation is a priority.
|
|
Hospital Affiliations:
|
UCSD Thornton Hospital, La Jolla
UCSD Medical Center, Hillcrest
|
|
Office Addresses:
|
Moores UCSD Cancer Center
3855 Health Sciences Drive
La Jolla, CA 92093
View Map | Driving Directions
UCSD Thornton Hospital
9300 Campus Point Drive
La Jolla, CA 92037
View Map | Driving Directions
UCSD Medical Center
200 West Arbor Drive
San Diego, CA 92103
View Map | Driving Directions
|
|
If you are new to this physician or would like assistance
selecting a doctor, please call our Physician Referral Service at (800) 926-8273. |
Last Updated June 25, 2009
|
;){kind=link}
;){kind=link}
;){kind=link}
;){kind=link}
;){kind=link}
;){kind=link}